GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced entering into a Settlement and Investment Agreement (the “Agreement”) with its contract manufacturing partner Cytovance Biologics. The signed Agreement, covers all work required to facilitate the registration of an investigational new drug (IND) filing with the U.S. Food and Drug Administration (“FDA”) of its lead investigational asset GTB-3650.
As temperatures soar to triple digits in areas of Southern California, U.S. Senator Alex Padilla (D-Calif.) and Representative Judy Chu (D-Calif.) were in Los Angeles today along with union representatives and workers to advocate for federal workplace heat stress protections.
Colorado Governor Jared Polis has appointed Sarah B. Wallace, a Litigation Partner in Ballard Spahr’s Denver office, to the Second Judicial District bench.